SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is surging dramatically on robust earnings and optimistic guidance, fueled by accelerating revenue, improved profitability, and a narrative positioning it as a key beneficiary of AI-driven demand for edge computing. The community is actively debating if this is a sustainable turnaround and short squeeze, or merely an overextended 'pump and dump' that will quickly reverse.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is a hot topic as it approaches its earnings release, grappling with a recent price target downgrade and reports of platform technical issues. Community discussion is sharply divided between concerns for a potential deep sell-off and bullish conviction that the current low valuation presents a significant buying opportunity for the crypto exchange.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is facing intense selling pressure, pushing the stock to multi-year lows as widespread market fears about AI's disruptive potential overshadow its strong fundamentals and substantial share buyback program. The community remains deeply divided on whether this makes it a generational buying opportunity or a company facing obsolescence.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy`s Co

Wendy's is trending amidst fervent community discussion fueled by acquisition rumors, which are sparking hopes for a short squeeze and a re-evaluation of its perceived undervaluation ahead of its anticipated earnings report.

Mega Fortune Co., Ltd. operates as an investment holding company. It specializes in delivering comprehensive IoT solutions and services across various industries. The company was founded in 2011 and is headquartered in Hong Kong.

Mega Fortune Co Ltd.

Mega Fortune Company Limited

MGRT is experiencing extreme volatility and frequent trading halts as a low-float Chinese IPO, fueling intense community debate between expectations of significant gains from a potential short squeeze and strong warnings of a classic pump and dump.

Astera Labs, Inc. is a global semiconductor company, which engages in the provision of hardware and software solutions for AI and cloud infrastructure applications to solve data, memory, and networking bottlenecks. It operates through the following geographical segments: Taiwan, China, United States, and Other. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Astera Labs (ALAB) is experiencing extreme volatility and a sharp sell-off despite beating earnings expectations and announcing a significant warrant deal with Amazon linked to $6.5 billion in product purchases. The community is fiercely debating whether this represents an overreaction and a 'screaming buy' opportunity in AI infrastructure or if concerns over margin compression, a CFO change, and broader tech sector repricing justify the dip.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco Systems is experiencing a significant sell-off despite beating revenue and EPS estimates, driven by a miss on adjusted gross margin. The gross margin contraction, attributed to rising memory chip costs and supply chain pressures, has sparked community debate over whether the market is overreacting to near-term profitability concerns amid strong long-term AI infrastructure demand.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is a trending topic following the approval of a critical SMR project in Romania and broad support for nuclear energy, including comments from Davos. The community is keenly discussing its potential to power AI data centers, juxtaposed with ongoing concerns about its pre-revenue status and significant market volatility.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X (CCCX) is trending as its merger target, Infleqtion, prepares for a vote to go public as INFQ, bolstered by recent NASA and DOE contracts for quantum sensing and energy grid optimization. The community expresses strong bullish sentiment, seeing Infleqtion as significantly undervalued compared to quantum peers and expecting its market valuation to align with its proven technology and partnerships after the merger.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is seeing intense debate as investors grapple with its perceived extreme undervaluation, robust GAAP profitability, and conservative guidance, which has spurred an "overdone" sell-off and fueled accusations of market manipulation amidst high short interest and broader fintech sector pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company went public in 2019 at a post-money valuation of $480 million, according to the report.&nbsp;</li><li>InMode has been facing declining sales and profits since 2023.</li><li>On January 9, the&nbsp;company said it anticipated its fourth-quarter sales to fall within a tight range of $103.6 million to $103.8 million.</li></ul>InMode stock became the talk of the town on Monday after a report stated that the company is set to be acquired by&nbsp;an investment fund in a deal that values the firm at roughly $1.1 billion, marking a 25% premium over its current Nasdaq trading value of $882 million.&nbsp;According to a Calcalist&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.calcalist.co.il/market/article/hjurxpfizl">report</a>, the transaction will result in InMode being taken private and removed from public trading.<a href="https://stocktwits.com/symbol/INMD">InMode stock</a> traded over 13% higher on Monday morning.&nbsp;<h2 class="st-heading-2">Background and Valuation</h2>Founded in 2008 by Moshe Mizrahi, the firm's CEO, and Michael Kreindel, the firm's Chief Technology Officer, the company originally developed advanced minimally invasive aesthetic treatments using radio frequency (RF) technology. It went public in 2019 at a post-money valuation of $480 million and reached a peak market value of $7 billion in 2021.Following the report, retail sentiment around the stock jumped to ‘bullish’ from ‘neutral’ territory the previous day amid ‘high’ message volume levels on Stocktwits.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_26_092338_png_08dfdb451a.webp" alt="INMD’s Sentiment Meter and Message Volume as of 09:40 a.m. ET on Jan. 26, 2026 | Source: Stocktwits" width="928" height="106"><figcaption>INMD’s Sentiment Meter and Message Volume as of 09:40 a.m. ET on Jan. 26, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Financial Challenges</h2>According to the report, InMode has been facing declining sales and profits since 2023, partly due to rising interest rates in the U.S. and an economic slowdown that affected financing for doctors purchasing its devices.&nbsp;The U.S. Food and Drug Administration’s (FDA) warning last October about health problems linked to some radiofrequency (RF) microneedling devices in general affected the stock.&nbsp;On January 9, the&nbsp;company said it anticipated its fourth-quarter (Q4) sales to fall within a tight range of $103.6 million to $103.8 million, below the analysts' consensus estimate of $104.64 million, according to FiscalAI data. Furthermore, the company’s 2025 revenue outlook of $370.2 million to $370.4 million is also below the analysts' consensus estimate of $371 million.INMD stock has declined by over 8% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/crwv-stock-soars-nvidia-2-billion-investment-ai-infrastructure/cmy7qzrR4h2">CRWV Stock Soars 10% Pre-Market As Nvidia Invests $2B To Expand AI Factory Network</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 A worker produces medical instrument at Shandong Yixing Medical Instrument Co., Ltd.

INMD Stock Jumped Nearly 13% Today – What’s Powering The Rally?

According to a Calcalist report, the company is set to go private after a $1.1 billion acquisition by a fund. 

Equity

<ul class="summary-bullets"><li>Median overall survival was 16 months for the combination versus 11.9 months for the group that received nab-paclitaxel alone.</li><li>Earlier data from the same trial showed a roughly 30% reduction in the risk of disease progression for participants treated with relacorilant plus nab-paclitaxel.</li><li>ROSELLA enrolled 381 women with platinum-resistant ovarian cancer across multiple regions.</li></ul>Corcept Therapeutics Inc. (CORT) on Thursday announced positive clinical results from its Phase 3 ROSELLA study evaluating the experimental drug relacorilant combined with nab-paclitaxel chemotherapy in women with platinum-resistant ovarian cancer.The company said the study hit its key survival goal, underscoring potential new hope for patients.&nbsp;<h2 class="st-heading-2">Positive Survival Results</h2>In the ROSELLA trial, patients receiving relacorilant with nab-paclitaxel saw their risk of death drop by about 35% compared with those given the chemotherapy alone.Median overall survival was 16.0 months for the combination versus 11.9 months for the group that received nab-paclitaxel alone, the company said.Following the results,&nbsp;<a href="https://stocktwits.com/symbol/CORT">Corcept stock</a> traded over 14% higher on Thursday morning. On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘bearish’ territory the previous day. Message volume changed to ‘low’ from ‘extremely low’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_22_103211_png_944b3daf2a.webp" alt="CORT’s Sentiment Meter and Message Volume as of 11:00 a.m. ET on Jan. 22, 2026 | Source: Stocktwits" width="929" height="104"><figcaption>CORT’s Sentiment Meter and Message Volume as of 11:00 a.m. ET on Jan. 22, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Progression-Free Survival</h2>Earlier data from the same trial showed a roughly 30% reduction in the risk of disease progression for participants treated with relacorilant plus nab-paclitaxel. Safety findings for the combination therapy align with established profiles, with no new adverse events emerging, suggesting the drug can deliver a meaningful clinical benefit without adding extra risk.<blockquote>“The addition of relacorilant to nab-paclitaxel, a trusted and effective chemotherapy, is positioned to become a new standard-of-care treatment for patients with platinum-resistant ovarian cancer, due to its overall survival benefit, well-tolerated side effect profile and oral administration.”-Alexander B. Olawaiye, Principal Investigator, ROSELLA Trial</blockquote>ROSELLA enrolled 381 women with platinum-resistant ovarian cancer across multiple regions, including the United States, Europe, South Korea, Brazil, Argentina, Canada, and Australia.CORT stock has declined by 31% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/netflix-warner-bros-deal-paramount-seeks-wbd-shareholder-suppot/cmUzzULR4QC">Netflix-Warner Bros. Deal: Paramount Seeks WBD Shareholder Support To Counter Amended NFLX Transaction, Extends Tender Offer</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Corcept Therapeutics logo is seen displayed on a smartphone screen. 

Why Did Corcept Therapeutics Stock Surge Over 14% Today?

In the ROSELLA trial, patients receiving relacorilant with nab-paclitaxel saw their risk of death drop by about 35% compared with those given the chemotherapy alone.

<ul class="summary-bullets"><li>Under the agreement, Janux will manage preclinical development through IND submission.</li><li>Bristol Myers Squibb will hold the IND, oversee subsequent clinical development, and lead global commercialization efforts.</li><li>The deal provides Janux with up to $50 million in upfront and near-term milestone payments.</li></ul>Janux Therapeutics, Inc. (JANX) announced on Thursday that it has entered a strategic collaboration with Bristol Myers Squibb to advance the development of a new tumor-activated therapy.&nbsp;The partnership focuses on a yet-to-be-disclosed solid tumor target expressed across multiple cancer types, aiming to expand treatment options for patients worldwide.<h2 class="st-heading-2">Collaboration Details</h2>Under the agreement, Janux will manage preclinical development through IND submission, whileBristol Myers Squibb will hold the IND, oversee subsequent clinical development, and lead global commercialization efforts.&nbsp;The collaboration ensures Janux remains actively engaged, supporting the completion of the first Phase 1 clinical study alongside Bristol Myers Squibb.<blockquote>“This collaboration marks a significant milestone for Janux, validating the strength of our tumor-activated platforms and expanding our reach in solid tumor oncology.”&nbsp;- David Campbell, President and CEO, Janux</blockquote>Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/JANX">Janux Therapeutics’ stock</a> traded over 8% higher in Thursday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘high’ from ‘low’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">Financial Terms</h2>The deal provides Janux with up to $50 million in upfront and near-term milestone payments. Additional development, regulatory, and commercial milestones could total roughly $800 million. Additionally, Janux will receive tiered royalties on worldwide product sales, giving the company potential long-term revenue streams if the therapy succeeds.This tie-up will use Janux’s proprietary technologies, including its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. These platforms are designed to enhance the immune system targeting of tumors while minimizing off-target effects.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/netflix-warner-bros-deal-paramount-seeks-wbd-shareholder-suppot/cmUzzULR4QC">Netflix-Warner Bros. Deal: Paramount Seeks WBD Shareholder Support To Counter Amended NFLX Transaction, Extends Tender Offer</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 A staff member of the Baden-Württemberg State Health Authority is pipetting corona samples during an experiment.

Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb

The company, along with Bristol Myers Squibb, will develop a new tumor-activated therapy.

<ul class="summary-bullets"><li>The company is running a Phase III study known as FLAMINGO-01, which is testing GLSI-100.</li><li>The approval follows the submission of manufacturing and stability data tied to multiple production runs.</li><li>More than 1,000 patients have already been screened for FLAMINGO-01.</li></ul>Greenwich LifeSciences, Inc. (GLSI) announced on Thursday that it has cleared another regulatory step in the development of its breast cancer immunotherapy as the company advances its late-stage clinical program.&nbsp;The clinical-stage biotechnology firm is running a Phase III study known as FLAMINGO-01, which is testing GLSI-100, a therapy designed to reduce the risk of cancer returning in certain breast cancer patients.<h2 class="st-heading-2">FDA Manufacturing Clearance</h2>The company disclosed that the Food and Drug Administration (FDA) has reviewed and authorized the use of its first commercially produced batch of the GP2 drug product in the ongoing FLAMINGO-01 trial.&nbsp;Following the update,&nbsp;<a href="https://stocktwits.com/symbol/GLSI">Greenwich LifeSciences stock</a> traded over 16% higher in Thursday’s premarket. However, on Stocktwits, retail sentiment around the stock remained in ‘bearish’ territory amid ‘low’ message volume levels.&nbsp;The approval follows the submission of manufacturing and stability data tied to multiple production runs completed over the past two years.<blockquote>"With our manufacturing investments in 2023 and 2024, and now the FDA's review and approval to use the first commercial lot of finished GP2 vials in FLAMINGO-01, we have taken major steps to further de-risk the filing of a BLA in the US.”-Snehal Patel, CEO, Greenwich LifeSciences</blockquote><h2 class="st-heading-2">Trial Progress And Early Signals</h2>More than 1,000 patients have already been screened for FLAMINGO-01, with enrollment continuing at a steady pace. One treatment arm involving patients without the HLA-A*02 marker has now completed enrollment, providing a larger dataset than earlier mid-stage research.&nbsp;Preliminary observations following the initial dosing period suggest a sharp decline in recurrence rates, though the company cautioned that the findings remain early and incomplete.GLSI stock has gained over 75% higher in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ondas-retail-chatter-up-in-a-week-what-is-driving-trader-interest/cmUzw1HR4Qo">Ondas Retail Chatter Up 131% In A Week — What's Driving Trader Interest?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A researcher works in the clinical-stage biopharmaceutical company Xencors new laboratory in Pasadena.

Why Did Greenwich LifeSciences Stock Soar Pre-Market Today?

The company disclosed that the Food and Drug Administration (FDA) has reviewed and authorized the use of its first commercially produced batch of the GP2 drug product in the ongoing FLAMINGO-01 trial. 

GLSI Stock Surges Pre-Market On Clearing FDA Manufacturing Step For Its Breast Cancer Trial

The company disclosed that the Food and Drug Administration (FDA) has reviewed and authorized the use of its first commercially produced batch of the GP2 drug product in the ongoing FLAMINGO-01 trial. 


<ul class="summary-bullets"><li>The company sees 2025 revenue of $616 million compared to the analysts’ consensus estimate of $606.03 million, according to Fiscal AI data.</li><li>BRIUMVI’s U.S. net product revenue expected to reach around $182 million in Q4 and $594 million in 2025.&nbsp;</li><li>TG Therapeutics stock rallies 9% higher in Wednesday’s premarket.&nbsp;</li></ul>TG Therapeutics, Inc. (TGTX) drew increased attention on Wednesday, with the stock seeing a 195% increase in retail chatter on Stocktwits over the last 24 hours following the company’s ambitious revenue outlook.&nbsp;On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI.<h2 class="st-heading-2">What Did Stocktwits Users Say?&nbsp;</h2><a href="https://stocktwits.com/symbol/TGTX">TG Therapeutics stock</a> traded over 9% higher in Wednesday’s premarket. On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_14_083034_png_390ef2e760.webp" alt="TGTX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 14, 2026 | Source: Stocktwits" width="933" height="108"><figcaption>TGTX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 14, 2026 | Source: Stocktwits</figcaption></figure>A Stocktwits user sounded optimistic about BRIUMVI achieving blockbuster status.<stembedurl>https://stocktwits.com/knowthyself/message/641747123</stembedurl>Another bullish user said the company’s ramp-up from Q3 to Q4 was impressive.&nbsp;<stembedurl>https://stocktwits.com/Uncle_Baby_Billy/message/641752748</stembedurl><h2 class="st-heading-2">Outlook Highlights&nbsp;</h2>TG Therapeutics expects BRIUMVI’s U.S. net product revenue to reach around $182 million in Q4 and $594 million for the full year of 2025. Global revenue for the year is estimated at $616 million compared to the analysts’ consensus estimate of $606.03 million, according to Fiscal AI data.&nbsp;Looking ahead, the company anticipates total global revenue between $875 million and $900 million for 2026, with U.S. BRIUMVI sales projected at $825 million to $850 million.BRIUMVI is a glycoengineered monoclonal antibody that targets CD20-expressing B-cells, a proven approach for treating autoimmune diseases like relapsing multiple sclerosis (RMS). By removing specific sugar molecules, BRIUMVI enhances B-cell depletion at lower doses.<h2 class="st-heading-2">Upcoming Clinical Milestones</h2>The company also teased three major milestones for 2026.&nbsp;TG Therapeutics plans to release pivotal topline data for the ENHANCE trial, which evaluates Day 1 and Day 15 intravenous doses of BRIUMVI, by mid-2026. Preliminary Phase 1 data for azer-cel in Progressive multiple sclerosis (MS) will be shared in the latter half of the year.&nbsp;Pivotal topline results for subcutaneous BRIUMVI are expected by year-end 2026 or early 2027.&nbsp;TGTX stock has declined by over 6% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-nrxp-stock-surge-pre-market-today/cmULXc2R4eL">Why Did NRXP Stock Surge 21% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Biology lab technician removes a freeze-dried sample from a container in a laboratory.

Retail Traders Are Piling Into TG Therapeutics – What’s Driving The Chatter?

On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI.

Betting on a Boom: 3 Healthcare ETFs for 2026 and Beyond

After a late-2025 rebound eased policy fears, healthcare ETFs like IXJ are gaining attention as investors position for a sector comeback in 2026.

Spotlight on Health ETFs as NVO & LLY Cut Obesity Drug Price in China

Novo Nordisk cuts Wegovy prices in China, which may shift investor focus toward diversified healthcare ETFs.

<ul class="summary-bullets"><li>MFN pricing extended nationwide through Medicaid and to future new medicines.</li><li>Steep direct-to-patient discounts rolled out via TrumpRx, including $35 insulin.</li><li>Additional pharma companies, including Johnson &amp; Johnson, are expected to ink similar deals next week.</li></ul>U.S. President Donald Trump on Friday announced nine new agreements with pharmaceutical companies to lower prescription drug prices for Americans to the lowest levels paid in other developed nations, under what the administration calls a “most-favored-nation” (MFN) pricing framework.With these additions, 14 of the 17 pharmaceutical companies targeted by the administration in August have now signed on.<h2 class="st-heading-2">Big Pharma Roster Expands</h2>The companies named in Friday’s agreements are Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi.Trump said additional companies, including Johnson &amp; Johnson, are expected to announce similar agreements next week, as the administration continues to expand the program.<h2 class="st-heading-2">Medicaid Savings And Future Drug Pricing</h2>The White House said the agreements apply to drugs used to treat an array of expensive, long-term conditions including type two diabetes, rheumatoid arthritis, multiple sclerosis, asthma, chronic obstructive pulmonary disease, hepatitis B and C, HIV and certain cancers.The administration said every state Medicaid program in the U.S. will benefit from MFN prices on products from the nine companies, which it estimates will save billions of dollars. The agreements also require MFN pricing for all new innovative medicines these companies bring to market.Trump also floated the idea of calling a meeting with insurance companies to discuss further ways to lower healthcare costs, suggesting insurers could significantly reduce prices or face alternative approaches that would direct savings to consumers.<h2 class="st-heading-2">Deep Discounts Via TrumpRx</h2>The administration said the companies are required to offer medicines at steep discounts off list prices when selling directly to American patients through TrumpRx, a government-backed direct-to-patient drug purchasing platform.The administration said patients would see steep price cuts, citing examples such as Amgen’s Repatha at $239 versus&nbsp;list price of $573, Bristol Myers Squibb’s Reyataz at $217 versus $1,449, and Sanofi’s Plavix at $16 versus $756, alongside similar reductions for drugs from Gilead, GSK, Merck and Novartis. The administration also said Sanofi will list its insulin products on TrumpRx at $35&nbsp;for every&nbsp;month’s supply.<h2 class="st-heading-2">Drugmakers Pledge Domestic Investment</h2>Trump said the participating companies have committed to invest at least $150 billion collectively in U.S. pharmaceutical manufacturing in the near term.The administration also said several companies will donate active pharmaceutical ingredients to the Strategic Active Pharmaceutical Ingredients Reserve to strengthen emergency preparedness. GSK will contribute 98.8 kg of Albuterol, Bristol Myers Squibb will contribute tablets representing 6.5 tons of Apixaban, and Merck will contribute 3.5 tons of Ertapenem.<h2 class="st-heading-2">How Did Stocktwits React?</h2>On Stocktwits, Health Care Select Sector SPDR Fund (XLV) showed 'bearish' retail sentiment amid 'high' message volume, while iShares Global Healthcare ETF (IXJ) saw 'bullish' sentiment with 'high' activity.<a href="https://stocktwits.com/symbol/XLV">XLV</a> and&nbsp;<a href="https://stocktwits.com/symbol/IXJ">IXJ</a> have risen 14% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trump announced his plan to lower drug prices would tie their cost to drug prices paid in foreign nations. (Photo by Andrew Harnik/Getty Images)

Trump Locks In Drug-Price Cuts With Roche, Novartis, Merck — More Big Pharma Deals Coming Next Week

The deals expand the pricing program to several drugmakers in exchange for temporary tariff relief.

<ul class="summary-bullets"><li>The Trump administration is preparing a Section 301 investigation to assess whether U.S. trading partners underpay for prescription drugs, a move that could pave the way for new tariffs.</li><li>Earlier this month, the White House confirmed generic drugs would be excluded from potential duties, reversing earlier discussions under the Section 232 national security review.</li><li>The probe expands Trump’s broader effort to pressure pharmaceutical companies and foreign governments to “equalize” drug prices globally.</li></ul>President Donald Trump’s administration reportedly is stepping up pressure on U.S. trading partners over drug costs, preparing a Section 301 investigation under the Trade Act of 1974 to determine whether countries are underpaying for prescription medicines.The move could pave the way for new tariffs and marks a renewed escalation in Trump’s campaign to “equalize” drug prices globally, according to a Financial Times&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/bce66d6e-57f7-40a2-8225-06a8f50ff657">report</a>, citing three people familiar with the matter.Trump has long argued Americans pay disproportionately high prices for the same drugs sold abroad, citing last week that “in London, you’d buy a certain drug for $130 … and in New York, you pay $1,300 for the same thing.”&nbsp;U.S. drug prices average nearly three times higher than in other developed economies, according to the Rand Corporation. Novo Nordisk’s Ozempic, for instance, costs about $936 per month in the U.S., versus $147 in Canada and $83 in France, KFF data show.<h2 class="st-heading-2">Generic Drugs Excluded From Tariff Plans</h2>Earlier this month, the White House<a href="https://stocktwits.com/news-articles/markets/equity/trump-walks-back-generic-drug-tariffs-after-white-house-clash-over-prices-supply-risks/ch67JdhR30E"> said it isn’t planning tariffs on generic drugs</a>, narrowing the scope of its trade actions. Officials had been weighing such duties under Section 232 of the Trade Expansion Act, which permits tariffs on national security grounds.White House spokesman Kush Desai said the administration “is not actively discussing imposing Section 232 tariffs against generic pharmaceuticals.” The Commerce Department also said such tariffs were unlikely, marking a reversal from Trump’s 2023 campaign pledge to restore domestic production of all essential medicines.Advisers, including members of the Domestic Policy Council and health aide Theo Merkel, warned tariffs on generics could raise prices and cause shortages, given that India supplies nearly half of U.S. generic drugs. Commerce officials, however, continue to explore quotas or incentives to rebuild U.S. drug manufacturing capacity.<h2 class="st-heading-2">Broader Pharma Trade Push&nbsp;</h2>The Section 301 move expands Trump’s broader effort to tie drug pricing policy to trade leverage. Earlier this year, he demanded that pharmaceutical companies offer the U.S. their best global price or face penalties.Major firms, including Pfizer, AstraZeneca, Novo Nordisk, and Eli Lilly, have all held pricing talks with the White House. Trump previously reached a deal with the EU to cap drug import tariffs at 15% and is negotiating with the U.K. for lower duties in exchange for higher payments to drugmakers.While Trump last month threatened 100% tariffs on branded drugs to force companies to expand U.S. manufacturing, those measures have yet to materialize. Officials said firms will be given time to invest domestically and demonstrate pricing reforms.Desai said the White House is pursuing a “multi-faceted approach” that could include federal grants or loans, potentially with funding from foreign partners like Japan, to strengthen U.S. drug supply chains and reduce dependence on imports.<h2 class="st-heading-2">Stocktwits Traders See Muted Interest For Healthcare ETFs</h2>On Stocktwits, retail sentiment toward the Health Care Select Sector SPDR Fund (XLV) was ‘bearish’ and toward the iShares Global Healthcare ETF (IXJ) was ‘neutral,’ both amid ‘low’ message volume.So far this year,&nbsp;<a href="https://stocktwits.com/symbol/XLV">XLV</a> is up 7%, while&nbsp;<a href="https://stocktwits.com/symbol/IXJ">IXJ</a> has gained 9%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump answers questions after making an announcement on “significant medical and scientific findings for America’s children” in the Roosevelt Room of the White House on September 22, 2025. (Photo by Andrew Harnik/Getty Images)

Trump Steps Up Pressure On Trading Partners Over Drug Costs, Plans Section 301 Review: Report

The probe expands Trump’s broader effort to pressure pharmaceutical companies and foreign governments to “equalize” drug prices globally.

 If the AI Bubble Bursts, Here Are Some Defensive ETFs to Consider 

As AI-fueled gains spark bubble warnings, investors are eyeing defensive ETFs in consumer staples, utilities and healthcare for safety. 

BlackRock Institutional Trust Company N.A. - iShares Global Healthcare ETF

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

With earnings season underway and rate-cut expectations shifting, the next move in the S&P 500 could set the tone for 2026. Are bulls still in control, or is volatility about to pick up? Cast your vote.

Current Price	$100.51
Prev Close	$100.36
Open	$100.24
Dividend Yield	N/A
50-Day Moving Average	$98.32
Beta	N/A
Avg. Volume	449,317.95
PE Ratio	N/A

52-Week High	$100.98
52-Week Low	$80.68
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

IXJ
iShares Global Healthcare ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IXJ News

IXJiShares Global Healthcare ETF